{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:30:49Z","timestamp":1792449049420,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.vascn.2023.107299","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T19:50:40Z","timestamp":1690228240000},"page":"107299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparing the sensitivity of cross-over and parallel study designs for QTc assessment: An analysis based on a single large study of moxifloxacin in 48 nonhuman primates"],"prefix":"10.1016","volume":"123","author":[{"given":"Derek J.","family":"Leishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Holdsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek D.","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2023.107299_bb0005","series-title":"ICH S7A: Safety pharmacology studies for human pharmaceuticals","author":"Anonymous","year":"2000"},{"key":"10.1016\/j.vascn.2023.107299_bb0010","series-title":"ICH S7B: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals","author":"Anonymous","year":"2005"},{"key":"10.1016\/j.vascn.2023.107299_bb0015","series-title":"ICH S9: Nonclinical evaluation for anticancer pharmaceuticals","author":"Anonymous","year":"2009"},{"key":"10.1016\/j.vascn.2023.107299_bb0020","series-title":"ICH E14\/S7B implementation working group - clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential. Questions and answers","author":"Anonymous.","year":"2022"},{"issue":"3","key":"10.1016\/j.vascn.2023.107299_bb0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pst.454","article-title":"Review of the statistical analysis of the dog telemetry study","volume":"10","author":"Aylott","year":"2011","journal-title":"Pharmaceutical Statistics"},{"key":"10.1016\/j.vascn.2023.107299_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107067","article-title":"The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies","volume":"109","author":"Baublits","year":"2021","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107299_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13103","article-title":"Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis","author":"Chui","year":"2021","journal-title":"Clinical and Translational Science"},{"issue":"2","key":"10.1016\/j.vascn.2023.107299_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bph.12484","article-title":"Detection of QTc interval prolongation using jacket telemetry in conscious non-human primates: Comparison with implanted telemetry","volume":"171","author":"Derakhchan","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2023.107299_bb0045","series-title":"The Design of Experiments","author":"Fisher","year":"1935"},{"issue":"8","key":"10.1016\/j.vascn.2023.107299_bb0050","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0091270010381498","article-title":"Population pharmacokinetic and concentration\u2014QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies","volume":"51","author":"Florian","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2023.107299_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2023.107253","article-title":"Comparison of validity of standard nonclinical group size selection versus standard clinical group sizes for nonhuman primate QTc prolongation evaluation","volume":"120","author":"Holdsworth","year":"2023","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2023.107299_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2011.08.006","article-title":"Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the safety pharmacology society","volume":"65","author":"Leishman","year":"2012","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107299_bb0065","series-title":"EnvStats: An R package for environmental statistics","author":"Millard","year":"2013"},{"key":"10.1016\/j.vascn.2023.107299_bb0070","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2022"},{"key":"10.1016\/j.vascn.2023.107299_bb0075","article-title":"Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14\/S7B Q&as","volume":"107270","author":"Rossman","year":"2023","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107299_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/43.suppl_2.69","article-title":"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: A comparison in humans and other mammalian species","volume":"43","author":"Siefert","year":"1999","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.vascn.2023.107299_bb0085","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and Proarrhythmia risk (ICH E14\/S7B updates)","author":"Strauss","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2023.107299_bb0090","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","author":"Vargas","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871923000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871923000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:07:37Z","timestamp":1761005257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871923000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":18,"alternative-id":["S1056871923000503"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2023.107299","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the sensitivity of cross-over and parallel study designs for QTc assessment: An analysis based on a single large study of moxifloxacin in 48 nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2023.107299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107299"}}